Bioresorbable Coronary Stents Market to Grow with a CAGR of 15.29% through 2028
Advancement in technology and Growing Prevalence of Coronary Artery
Disease (CAD) is expected to drive the North America Bioresorbable Coronary
Stents Market growth in the forecast period, 2024-2028.
According to TechSci Research report, “North
America Bioresorbable Coronary Stents Market –Industry Size, Share,
Trends, Competition Forecast & Opportunities, 2028”, the North
America Bioresorbable Coronary Stents Market stood at USD 45.24 million in 2022
and is anticipated to grow with a CAGR of 15.29% in the forecast period,
2024-2028. The awareness among individuals regarding Bioresorbable Coronary
Stents has led to favorable market conditions for the North America Bioresorbable
Coronary Stents market. Several factors contribute to the growth of various Bioresorbable
Coronary Stents products.
The increasing incidence of coronary artery disease
(CAD) North Americaly is a significant driver for the bioresorbable coronary
stents market. CAD is a leading cause of morbidity and mortality worldwide, and
the demand for effective treatment options continues to rise. As awareness of
CAD and its risk factors increases, more patients are seeking early
intervention and treatment, driving the demand for innovative stent solutions
like bioresorbable stents.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "North America Bioresorbable Coronary Stents Market.”
Ongoing research and development in the field of
bioresorbable stents have led to advancements in materials and manufacturing
techniques. Newer stent designs, improved biodegradable materials, and enhanced
delivery systems have made these devices more reliable and easier to implant.
These technological advancements have increased the acceptance of bioresorbable
stents among healthcare providers, further driving market growth, which will
further fuel market growth.
In August 2023, Medtronic presents new data from its
Evolut Low Risk Trial at the Transcatheter Cardiovascular Therapeutics (TCT)
conference, showing that the Evolut TAVR platform is superior to surgery for
low-risk patients.
The clinical benefits and superior outcomes associated
with bioresorbable coronary stents are significant drivers for the growth of
the North America bioresorbable stents market. They provide a compelling case
for healthcare professionals and patients alike, offering a safer and more
patient-friendly alternative to traditional metallic stents. As clinical
evidence continues to support the efficacy and safety of bioresorbable stents,
their adoption is expected to increase, contributing to the expansion of the
market.
In today's fast-paced world, Bioresorbable stents are
designed to gradually dissolve in the body over time. This means that patients
may not need to take long-term dual antiplatelet therapy (DAPT), which is
required with traditional metallic stents. The absence of DAPT reduces the recovery
time and allows patients to return to their daily activities more quickly. Bioresorbable
stents offer a reduced risk of late complications like in-stent restenosis and
stent thrombosis, which can be time-consuming and challenging to manage. This
minimization of complications ensures that patients experience fewer medical
setbacks and allows them to maintain their active lifestyles. In a fast-paced
world, individuals value their quality of life. Bioresorbable stents contribute
to an improved quality of life for patients. As these stents gradually
dissolve, patients do not have a permanent implant in their bodies, eliminating
any discomfort or awareness of a foreign object, which can have a significant
impact on overall well-being. The ability to personalize treatment is vital in
a fast-paced healthcare environment. Bioresorbable stents can be customized to
fit a patient's specific coronary anatomy, offering tailored solutions that
optimize outcomes. Personalized medicine ensures that patients receive the most
suitable treatment promptly. The rapid pace of technological advancements in
the medical field is essential for addressing the needs of the fast-paced
world. Bioresorbable stents benefit from these advancements, including improved
stent materials, designs, and manufacturing techniques, making them more
reliable, user-friendly, and effective.
Regulatory bodies such as the U.S. Food and Drug
Administration (FDA) and the European Medicines Agency (EMA) have been
supportive of bioresorbable stents, provided they meet safety and efficacy
standards. As more bioresorbable stents receive regulatory approvals,
healthcare professionals gain confidence in their use, and the adoption of
these stents increases. The approval process ensures that these devices meet
stringent quality and safety standards, which is essential for market growth.
In recent times, Bioresorbable stents are designed to
provide temporary structural support to the coronary artery, similar to
traditional metallic stents, but with one key difference: they gradually
dissolve in the body over time. This unique feature reduces the risk of long-term
complications such as in-stent restenosis, which is the renarrowing of the
treated vessel. By eliminating the permanent presence of a foreign object in
the artery, bioresorbable stents lower the likelihood of complications that can
occur with metallic stents. In the past, patients receiving metallic stents
were required to take DAPT, a combination of blood-thinning medications, for an
extended period, typically up to one year or more. This regimen was essential
to prevent blood clots around the stent. Bioresorbable stents, however, have
been designed to reduce the need for prolonged DAPT, allowing patients to
discontinue these medications sooner. This flexibility is particularly useful
in minimizing the risk of bleeding and simplifying the treatment process. Bioresorbable
stents promote improved vessel healing compared to metallic stents. As the
stent dissolves, the vessel can return to its natural state more effectively.
This feature is crucial for maintaining long-term vessel functionality, which
can lead to better overall outcomes for CAD patients. However, the Limited
Long-Term Clinical Data may hinder market growth. Moreover, challenges related
to Cost and Reimbursement and Technical and Procedural Challenges may pose
obstacles to the Bioresorbable Coronary Stents market in the near future.
The North America Bioresorbable Coronary Stents Market
is segmented into brand, regional distribution, and company.
Based on its brand, the MeRes100 segment has emerged
as the predominant market leader, MeRes100 is celebrated for its clinical
innovation. It has undergone rigorous clinical trials to demonstrate its
efficacy and safety. Clinical evidence supporting the effectiveness of MeRes100
has been published, which has a positive impact on its adoption by healthcare
providers. Its innovative design and controlled degradation process contribute
to better vessel healing and restoration of natural vessel function, potentially
reducing complications associated with stent placement. This clinical efficacy
positions MeRes100 as a compelling choice for interventional cardiologists and
their patients. MeRes100 incorporates unique technological advancements that
set it apart from other bioresorbable stents. Its proprietary polymer
formulation and manufacturing processes have been optimized to ensure
controlled and predictable stent degradation, addressing concerns about late
scaffold discontinuity. These technological advantages contribute to the appeal
of MeRes100 as a next-generation bioresorbable stent, which may attract
healthcare providers and patients looking for state-of-the-art treatment
options.
Based on region, United States segment is expected to
grow during the forecast period. The region boasts a sophisticated
healthcare infrastructure, encompassing hospitals, clinics, and specialized
cardiac centers. These facilities are equipped with state-of-the-art technology
and staffed by highly skilled healthcare professionals adept in performing
coronary procedures. Furthermore, the United States maintains a robust
healthcare system that actively fosters technological advancements and
innovations. It serves as the headquarters for several prominent medical device
companies that make substantial investments in research and development,
thereby propelling the progress of bioresorbable coronary stents. The presence
of cutting-edge technologies and a wealth of expertise in this region underpins
its dominance in the market. However, the United States lags behind, with
limited prominence in this sector.
The Canada market is poised to be the fastest-growing
market, offering lucrative growth opportunities for Bioresorbable Coronary
Stents players during the forecast period. Factors such as the increasing
numbers of coronary stenting procedures due to the substantial patient
population afflicted with cardiovascular diseases, the area is also
experiencing a swift uptake of CE and FDA-approved devices. This, in turn,
results in robust regional sales revenue for bioresorbable coronary stents.
Also, the region has made significant investments in enhancing its healthcare
infrastructure, which includes the establishment of modern hospitals, cardiac
centers, and catheterization laboratories equipped with state-of-the-art
medical technologies. These developments empower healthcare providers to
deliver high-quality treatments, including the utilization of bioresorbable
coronary stents, to their patients. The presence of such facilities fosters the
expansion of the market.
Major companies operating in North America Bioresorbable
Coronary Stents Market are:
- Boston Scientific Corporation
- Medtronic Inc.
- Cordis Corp
- Biotronik Inc.
- Meril Life Sciences Pvt. Ltd.
- Abbott Laboratories Ind.
- Elixir Medical Corp
- REVA Medical, LLC
- Arterial Remodeling Technologies SA
Download Free Sample Report
Customers can also request for 10%
free customization on this report.
“The advancement in technology and Growing Prevalence
of Coronary Artery Disease (CAD) are key drivers of the Bioresorbable Coronary
Stents market. In recent years, the growing incidence of coronary artery
disease continues to rise North Americaly, there is a growing need for
effective treatment options. CAD is a leading cause of morbidity and mortality,
and bioresorbable coronary stents provide a solution that aligns with the
increasing patient population afflicted with this condition. To meet the
demands of the market, manufacturers are increasingly incorporating
cutting-edge technologies with high production efficiency. Rising consumer
acceptance and continuous product innovation will further ensure the growth of
the Bioresorbable Coronary Stents market in the coming years.,” said Mr. Karan
Chechi, Research Director with TechSci Research, a research-based management
consulting firm.
“North America Bioresorbable Coronary Stents
Market – Segmented By Brand (Magmaris, Magnitude, MeRes100, DESolve, Others),
By Region, Competition, Forecast, Opportunities, 2018-2028F”, has evaluated
the future growth potential of North America Bioresorbable Coronary Stents
Market and provides statistics & information on market size, structure and
future market growth. The report intends to provide cutting-edge market
intelligence and help decision makers take sound investment decisions. Besides,
the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in North America Bioresorbable
Coronary Stents Market.
Contact
Techsci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +13322586602
Email: [email protected]
Website: www.techsciresearch.com